Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.34 |
| ▸ | CXCR5 | P32302 | 4/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23971983 | 0.91 | HIF1A (0.33) | HIF1ACA12NPC1LMNAPKM | |
| SCHEMBL23971863 | 0.90 | KDM4E (0.39) | HIF1ACXCR5CA12 | |
| SCHEMBL25600975 | 0.89 | HIF1A (0.34) | HIF1ACXCR5CA12NPC1LMNA | |
| SCHEMBL25600970 | 0.88 | HIF1A (0.33) | HIF1ACXCR5CA12NPC1LMNA | |
| SCHEMBL23971934 | 0.88 | MAPK13 (0.35) | HIF1ACXCR5CA12 | |
| SCHEMBL23971893 | 0.88 | HIF1A (0.34) | HIF1ACXCR5CA12NPC1LMNA | |
| SCHEMBL23971843 | 0.87 | HIF1A (0.33) | HIF1ACA12 | |
| SCHEMBL23971771 | 0.86 | F2R (0.33) | HIF1ACXCR5CA12NPC1LMNA | |
| SCHEMBL23972079 | 0.86 | HIF1A (0.32) | HIF1ACA12 | |
| SCHEMBL23972032 | 0.86 | HIF1A (0.33) | HIF1ACXCR5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172204-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172204-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | COX5B, SQOR, UQCRB | HIF1A 2044/4885CXCR5 4860/4885CA12 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.